Federal Register / Vol. 88, No. 228 / Wednesday, November 29, 2023 / Notices 83405 

(2) Return the attached ‘‘Mailing List 

Update Form’’ (appendix 3). 

Becoming an Intervenor 

Eastern Shore has filed its application 

with the Commission and you may want 

to become an ‘‘intervenor’’ which is an 

official party to the Commission’s 

proceeding. Only intervenors have the 

right to seek rehearing of the 

Commission’s decision and be heard by 

the courts if they choose to appeal the 

Commission’s final ruling. An 

intervenor formally participates in the 

proceeding by filing a request to 

intervene pursuant to Rule 214 of the 

Commission’s Rules of Practice and 

Procedures (18 CFR 385.214). Motions 

to intervene are more fully described at 

https://www.ferc.gov/resources/guides/ 

how-to.asp. Please note that the 

Commission will not accept requests for 

intervenor status at this time. You must 

wait until the Commission receives a 

formal application for the Project, after 

which the Commission will issue a 

public notice that establishes an 

intervention deadline. 

Additional Information 

Additional information about the 

Project is available from the 

Commission’s Office of External Affairs, 

at (866) 208–FERC, or on the FERC 

website (www.ferc.gov) using the 

eLibrary link. https://elibrary.ferc.gov/ 

eLibrary/search. Click on the eLibrary 

link, click on ‘‘General Search’’ and 

enter the docket number in the ‘‘Docket 

Number’’ field. Be sure you have 

selected an appropriate date range. For 

assistance, please contact FERC Online 

Support at FercOnlineSupport@ferc.gov 

or toll free at (866) 208–3676, or for 

TTY, contact (202) 502–8659. The 

eLibrary link also provides access to the 

texts of all formal documents issued by 

the Commission, such as orders, notices, 

and rulemakings. 

Public sessions or site visits will be 

posted on the Commission’s calendar 

located at https://www.ferc.gov/newsevents/events along with other related 

information. 

Dated: November 22, 2023. 

Debbie-Anne A. Reese, 

Deputy Secretary. 

[FR Doc. 2023–26243 Filed 11–28–23; 8:45 am] 

BILLING CODE 6717–01–P 

DEPARTMENT OF ENERGY 

Federal Energy Regulatory 

Commission 

[Docket No. ER24–455–000] 

Electree LLC; Supplemental Notice 

That Initial Market-Based Rate Filing 

Includes Request for Blanket Section 

204 Authorization 

This is a supplemental notice in the 

above-referenced proceeding of Electree 

LLC’s application for market-based rate 

authority, with an accompanying rate 

tariff, noting that such application 

includes a request for blanket 

authorization, under 18 CFR part 34, of 

future issuances of securities and 

assumptions of liability. 

Any person desiring to intervene or to 

protest should file with the Federal 

Energy Regulatory Commission, 888 

First Street NE, Washington, DC 20426, 

in accordance with Rules 211 and 214 

of the Commission’s Rules of Practice 

and Procedure (18 CFR 385.211 and 

385.214). Anyone filing a motion to 

intervene or protest must serve a copy 

of that document on the Applicant. 

Notice is hereby given that the 

deadline for filing protests with regard 

to the applicant’s request for blanket 

authorization, under 18 CFR part 34, of 

future issuances of securities and 

assumptions of liability, is December 12, 

2023. 

The Commission encourages 

electronic submission of protests and 

interventions in lieu of paper, using the 

FERC Online links at http://

www.ferc.gov. To facilitate electronic 

service, persons with internet access 

who will eFile a document and/or be 

listed as a contact for an intervenor 

must create and validate an 

eRegistration account using the 

eRegistration link. Select the eFiling 

link to log on and submit the 

intervention or protests. 

Persons unable to file electronically 

may mail similar pleadings to the 

Federal Energy Regulatory Commission, 

888 First Street NE, Washington, DC 

20426. Hand delivered submissions in 

docketed proceedings should be 

delivered to Health and Human 

Services, 12225 Wilkins Avenue, 

Rockville, Maryland 20852. 

In addition to publishing the full text 

of this document in the Federal 

Register, the Commission provides all 

interested persons an opportunity to 

view and/or print the contents of this 

document via the internet through the 

Commission’s Home Page (http://

www.ferc.gov) using the ‘‘eLibrary’’ link. 

Enter the docket number excluding the 

last three digits in the docket number 

field to access the document. At this 

time, the Commission has suspended 

access to the Commission’s Public 

Reference Room, due to the 

proclamation declaring a National 

Emergency concerning the Novel 

Coronavirus Disease (COVID–19), issued 

by the President on March 13, 2020. For 

assistance, contact the Federal Energy 

Regulatory Commission at 

FERCOnlineSupport@ferc.gov or call 

toll-free, (886) 208–3676 or TYY, (202) 

502–8659. 

The Commission’s Office of Public 

Participation (OPP) supports meaningful 

public engagement and participation in 

Commission proceedings. OPP can help 

members of the public, including 

landowners, environmental justice 

communities, Tribal members and 

others, access publicly available 

information and navigate Commission 

processes. For public inquiries and 

assistance with making filings such as 

interventions, comments, or requests for 

rehearing, the public is encouraged to 

contact OPP at (202) 502–6595 or OPP@

ferc.gov. 

Dated: November 22, 2023. 

Debbie-Anne A. Reese, 

Deputy Secretary. 

[FR Doc. 2023–26241 Filed 11–28–23; 8:45 am] 

BILLING CODE 6717–01–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[FRL–11579–01–R9] 

Notice of Availability and Extension of 

Comment Period for the Preliminary 

Designation of Certain Stormwater 

Discharges Within Two Watersheds in 

Los Angeles County, California Under 

the National Pollutant Discharge 

Elimination System of the Clean Water 

Act 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice of availability; extension 

of comment period and correction. 

SUMMARY: The Environmental Protection 

Agency (EPA) Region 9 published a 

document in the Federal Register on 

November 2, 2023, soliciting comment 

on the preliminary designation of 

stormwater discharges from certain 

commercial, industrial, and institutional 

(CII) sites in two watersheds in Los 

Angeles County, California for 

regulation under the Clean Water Act 

(CWA) National Pollutant Discharge 

Elimination System (NPDES) permitting 

program. The November 2, 2023 notice 

of availability contained an incorrect 

email address for submitting comments 


ddrumheller on DSK120RN23PROD with NOTICES1
83406 Federal Register / Vol. 88, No. 228 / Wednesday, November 29, 2023 / Notices 

which is corrected below and the review 

and comment period is extended to 

provide a 60-day public comment 

period. All other information in the 

November 2, 2023 notice of availability 

is correct. 

DATES: Written comments must be 

received on or before January 3, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Eugene Bromley, EPA Region 9, Water 

Division, NPDES Permits Section; 

telephone (415) 972–3510; email 

address: bromley.eugene@epa.gov. 

Correction 

In the Federal Register of November 

2, 2023 in FRL–11427–01–R9, page 

75282, first column correct line after 

ADDRESSES to read: 

‘‘ADDRESSES: Comments should be 

submitted via email to the following 

address: R9RDA@epa.gov and include 

‘‘Comments on the 2023 Preliminary 

Designation’’ in the subject line.’’ 

Dated: November 22, 2023. 

Martha Guzman Aceves, 

Regional Administrator, EPA Region 9. 

[FR Doc. 2023–26226 Filed 11–28–23; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket Nos. FDA–2021–E–0792, FDA– 

2021–E–0793, and FDA–2021–E–0803] 

Determination of Regulatory Review 

Period for Purposes of Patent 

Extension; Olinvyk 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or the Agency) has 

determined the regulatory review period 

for Olinvyk and is publishing this notice 

of that determination as required by 

law. FDA has made the determination 

because of the submission of 

applications to the Director of the U.S. 

Patent and Trademark Office (USPTO), 

Department of Commerce, for the 

extension of a patent which claims that 

human drug product. 

DATES: Anyone with knowledge that any 

of the dates as published (see 

SUPPLEMENTARY INFORMATION) are 

incorrect may submit either electronic 

or written comments and ask for a 

redetermination January 29, 2024. 

Furthermore, any interested person may 

petition FDA for a determination 

regarding whether the applicant for 

extension acted with due diligence 

during the regulatory review period by 

May 28, 2024. See ‘‘Petitions’’ in the 

SUPPLEMENTARY INFORMATION section for 

more information. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. The https://

www.regulations.gov electronic filing 

system will accept comments until 

11:59 p.m. Eastern Time at the end of 

January 29, 2024. Comments received by 

mail/hand delivery/courier (for written/ 

paper submissions) will be considered 

timely if they are received on or before 

that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket Nos. FDA– 

2021–E–0792, FDA–2021–E–0793, and 

FDA–2021–E–0803 for ‘‘Determination 

of Regulatory Review Period for 

Purposes of Patent Extension; 

OLINVYK.’’ Received comments, those 

filed in a timely manner (see 

ADDRESSES), will be placed in the docket 

and, except for those submitted as 

‘‘Confidential Submissions,’’ publicly 

viewable at https://www.regulations.gov 

or at the Dockets Management Staff 

between 9 a.m. and 4 p.m., Monday 

through Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with § 10.20 (21 

CFR 10.20) and other applicable 

disclosure law. For more information 

about FDA’s posting of comments to 

public dockets, see 80 FR 56469, 

September 18, 2015, or access the 

information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

FOR FURTHER INFORMATION CONTACT: 

Beverly Friedman, Office of Regulatory 

Policy, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 51, 

Rm. 6250, Silver Spring, MD 20993, 

301–796–3600. 

SUPPLEMENTARY INFORMATION: 


ddrumheller on DSK120RN23PROD with NOTICES1